Navigation Links
Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases
Date:7/7/2009

THOUSAND OAKS, Calif., July 7 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,049 patients with advanced breast cancer met its primary and secondary endpoints and demonstrated superior efficacy compared to Zometa. Superiority was demonstrated for both delaying the time to the first on-study Skeletal Related Events (SREs)(fracture, radiation to bone, surgery to bone, or spinal cord compression) (hazard ratio 0.82, 95 percent CI: 0.71, 0.95), and delaying the time to the first-and-subsequent SREs (hazard ratio 0.77, 95 percent CI: 0.66, 0.89). Both results were statistically significant.

Overall, the incidence of adverse events and serious adverse events was consistent with what has previously been reported for these two agents. Of note, osteonecrosis of the jaw (ONJ), which had not been observed in previously reported Phase 3 studies with denosumab, was seen infrequently in both treatment groups. There was no statistically significant difference in the rate of ONJ between the two treatment arms. Infectious adverse events were balanced between the two treatment arms, as was overall survival and the time to cancer progression.

"We are extremely pleased with the outcome of this important study, which shows that denosumab can reduce or delay the serious complications of bone metastases in breast cancer patients better than the current standard of care, and with a favorable benefit/risk profile," said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen. "These results underscore the importance of the RANK Ligand pathway in bone disease, and offer the promise of improved care for patients with advanced breast cancer. We look forward to
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis
2. Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
3. Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
4. Study Demonstrates Efficacy of Pitavastatin in Elderly Patients
5. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
6. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
7. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
10. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
11. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the ... therapies for cardiovascular disease and overall health is pleased to ... 2014 and its outlook for 2015 from the CEO, Mr. ... We would like to take this opportunity to share ...
(Date:1/22/2015)... MINNEAPOLIS , Jan. 22, 2015  Bio-Techne Corporation (NASDAQ: ... launched Ella, the first member of the new Simple ... ProteinSimple brand.  This launch represents the re-branding of the ... The Simple Plex platform is a transformative immunoassay technology ...
(Date:1/22/2015)... NEWBURY PARK, Calif. , Jan. 22, 2015 ... drive the continued consolidation of localization purchasing in 2015, ... According to a recent study by market ... studied chose a single-source solution for their translation and ...
Breaking Medicine Technology:Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Bio-Techne Launches Simple Plex Platform 2Bio-Techne Launches Simple Plex Platform 3Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2
... CLEVELAND, Nov. 10 /PRNewswire/ -- JumpStart ... accelerates the progress of high growth early-stage businesses, ... in Checkpoint Surgical, LLC. A spinout of NDI ... is developing and commercializing a surgical handheld disposable ...
... Thoratec Corporation (Nasdaq: THOR ), a world ... support and restore failing hearts, said today that it ... Conference on Tuesday, November 10. , The presentation by ... begin at 8 a.m., Pacific Standard Time (11 a.m., ...
Cached Medicine Technology:JumpStart Invests in Checkpoint Surgical 2JumpStart Invests in Checkpoint Surgical 3
(Date:1/22/2015)... 2015 For over 20 years, Dr. David Cruz ... Vista area has treated just about every type of injury ... And for those same twenty-plus years, the team at ... injuries with the best possible doctor. With the combined ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Yesterday, ... Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were honored ... leadership in advancing biotechnology, biomedical science, medical device ... Olsen each received the “2014 Life Sciences Champion” ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Payday lending ... vulnerable communities and cause financial distress to the states ... analysts at Howard University’s Center on Race and Wealth. ... in economic activity, payday loans at the same time ...
(Date:1/22/2015)... 2015 Compare-autoinsurance.org has released a new blog post ... auto insurance policy . , Some types of vehicles ... check the newly released blog post to see if their vehicle ... damaged vehicles are some of the cars that cannot be covered ...
(Date:12/26/2014)... 26, 2014 The US represents the largest ... In 2013, GlobalData’s forecast estimates that sales of branded therapies ... due to the high incidence of the disease, high drug ... Japan, and China. Increased sales of CRC therapies over the ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... of antivirals such as Tamiflu best for this ... U.S. health officials said Tuesday that they,re seeing some ... to spread across the country, and that this high-risk ... is suspected. , "Pregnant women are at higher risk ...
... N.J., May 13 Celator Pharmaceuticals today announced that ... at the 2009 BIO International Convention in Atlanta. ... update on the company,s progress with two ongoing Phase ... myeloid leukemia (AML) patients and first-relapse AML patients. ...
... ORANGE COUNTY, Calif., May 13 Beckman Coulter, ... developer, manufacturer, and marketer of products that simplify, ... that the Federal Trade Commission has terminated its ... 1976, as amended, of the company,s pending acquisition ...
... May 13 /PRNewswire-Asia/ -- China Medicine Corporation,(OTC Bulletin ... developer,and a leading distributor of prescription and over ... dietary supplements, and,medical devices and medical formulations, today ... First Quarter 2009 Highlights:, ...
... awarded a 5-year contract to provide medical transcription service to the ... at Pueblo. , ... Hauppauge, NY (PRWEB) May 13, ... awarded a 5-year contract to provide medical transcription services for the ...
... new core and elective clinical rotations at Danbury Hospital in Danbury, CT. ... ... School of Medicine is pleased to announce it will add several new ... on the East Coast. The new placements will be located at Danbury ...
Cached Medicine News:Health News:Pregnant Women Should Take Flu Drugs Promptly 2Health News:Pregnant Women Should Take Flu Drugs Promptly 3Health News:Pregnant Women Should Take Flu Drugs Promptly 4Health News:Pregnant Women Should Take Flu Drugs Promptly 5Health News:Pregnant Women Should Take Flu Drugs Promptly 6Health News:Pregnant Women Should Take Flu Drugs Promptly 7Health News:Pregnant Women Should Take Flu Drugs Promptly 8Health News:Pregnant Women Should Take Flu Drugs Promptly 9Health News:Pregnant Women Should Take Flu Drugs Promptly 10Health News:Celator(R) Pharmaceuticals to Present at 2009 BIO International Convention 2Health News:Beckman Coulter Pending Acquisition of Olympus Diagnostics Systems Passes Milestone with U.S. Regulatory Approval 2Health News:China Medicine Announces First Quarter 2009 Results 2Health News:China Medicine Announces First Quarter 2009 Results 3Health News:China Medicine Announces First Quarter 2009 Results 4Health News:China Medicine Announces First Quarter 2009 Results 5Health News:China Medicine Announces First Quarter 2009 Results 6Health News:China Medicine Announces First Quarter 2009 Results 7Health News:China Medicine Announces First Quarter 2009 Results 8Health News:China Medicine Announces First Quarter 2009 Results 9Health News:China Medicine Announces First Quarter 2009 Results 10Health News:China Medicine Announces First Quarter 2009 Results 11Health News:China Medicine Announces First Quarter 2009 Results 12Health News:China Medicine Announces First Quarter 2009 Results 13Health News:ZyDoc Medical Transcription Wins Colorado Mental Health Institute Contract Award 2Health News:ZyDoc Medical Transcription Wins Colorado Mental Health Institute Contract Award 3Health News:Ross University School of Medicine Expands Clinical Rotations on East Coast 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: